NCT06963697 2026-01-15
Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Jaime Leandro Foundation for Therapeutic Cancer Vaccines
Available
Clinical Trials
32 trialsNCT03626285 2026-01-02
Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders
OHSU Knight Cancer Institute
Available
NCT06841874 2025-12-24
Tale EAP
Nuvation Bio Inc.
No longer available
NCT07262970 2025-12-04
Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor
Rezolute
Available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT02632994 2025-09-29
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Eli Lilly and Company
Available
NCT04087889 2025-09-29
Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer
Hope Biosciences Research Foundation
No longer available
NCT05162443 2025-08-26
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Bristol-Myers Squibb
Approved for marketing
NCT01370330 2025-07-22
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
University of California, San Francisco
Available
NCT06980506 2025-05-22
MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
Monopar Therapeutics
Available
NCT06980519 2025-05-22
MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
Monopar Therapeutics
Available
NCT05572970 2025-04-30
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
Agenus Inc.
Available
NCT05592743 2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing
NCT04853602 2024-08-12
IFx-Hu2.0 Expanded Access Program
TuHURA Biosciences, Inc.
Available
NCT05760586 2024-08-12
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Day One Biopharmaceuticals, Inc.
Approved for marketing
NCT02473497 2024-06-26
Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients
Pfizer
No longer available
NCT05014607 2024-05-09
InHeVac01
University Hospital Tuebingen
Available
NCT06238583 2024-02-02
Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors
Bayer
No longer available
NCT03138629 2023-11-22
Expanded Access to VAL-083
Kintara Therapeutics, Inc.
No longer available
NCT04869501 2023-04-28
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
I-Mab Biopharma US Limited
No longer available
NCT03126643 2021-11-29
Expanded Access to Nivolumab (Opdivo)
Bristol-Myers Squibb
Approved for marketing
NCT01200017 2021-05-27
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
University of California, San Francisco
No longer available
NCT01377532 2020-05-06
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
University of California, San Francisco
Approved for marketing
NCT03424473 2020-02-25
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Seagen Inc.
No longer available
NCT02715843 2019-10-11
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
Molecular Templates, Inc.
No longer available
NCT03529539 2019-03-06
PSV
EpicentRx, Inc.
No longer available
NCT02955446 2019-02-01
Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies
University of Colorado, Denver
No longer available
NCT03079687 2017-10-25
Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AstraZeneca
Approved for marketing
NCT01606982 2017-02-17
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Astellas Pharma Inc
Approved for marketing
NCT01432483 2015-01-26
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
Eisai Inc.
No longer available
NCT00481559 2014-01-17
Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity
BTG International Inc.
Approved for marketing
NCT00805337 2008-12-09
ADLG3
Pasche, Boris, M.D.
No longer available